Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes - PubMed (original) (raw)

. 2013 Feb 7;121(6):877-83.

doi: 10.1182/blood-2012-06-432500. Epub 2012 Nov 6.

Kanchan Rao, Prakash Satwani, Kai Lehmberg, Ingo Müller, Dandan Li, Mi-Ok Kim, Alain Fischer, Sylvain Latour, Petr Sedlacek, Vincent Barlogis, Kazuko Hamamoto, Hirokazu Kanegane, Sam Milanovich, David A Margolis, David Dimmock, James Casper, Dorothea N Douglas, Persis J Amrolia, Paul Veys, Ashish R Kumar, Michael B Jordan, Jack J Bleesing, Alexandra H Filipovich

Affiliations

Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes

Rebecca A Marsh et al. Blood. 2013.

Abstract

There have been no studies on patient outcome after allogeneic hematopoietic cell transplantation (HCT) in patients with X-linked inhibitor of apoptosis (XIAP) deficiency. To estimate the success of HCT, we conducted an international survey of transplantation outcomes. Data were reported for 19 patients. Seven patients received busulfan-containing myeloablative conditioning (MAC) regimens. Eleven patients underwent reduced intensity conditioning (RIC) regimens predominantly consisting of alemtuzumab, fludarabine, and melphalan. One patient received an intermediate-intensity regimen. Survival was poor in the MAC group, with only 1 patient surviving (14%). Most deaths were from transplantation-related toxicities, including venoocclusive disease and pulmonary hemorrhage. Of the 11 patients who received RIC, 6 are currently surviving at a median of 570 days after HCT (55%). Preparative regimen and HLH activity affected outcomes, and of RIC patients reported to be in remission from HLH, survival is 86% (P = .03). We conclude that MAC regimens should not be used for patients with XIAP deficiency. It is possible that the loss of XIAP and its antiapoptotic functions contributes to the high incidence of toxicities observed with MAC regimens. RIC regimens should be pursued with caution and, if possible, efforts should be made to ensure HLH remission before HCT in these patients.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Kaplan-Meier survival analyses. Shown are analyses of 1-year survival (A), long-term survival (B), and survival stratified by reported HLH status at the time of transplantation (C; P = .035) in patients treated with MAC or RIC regimens.

Similar articles

Cited by

References

    1. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–2373. - PubMed
    1. Horne A, Janka G, Maarten Egeler R, et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol. 2005;129(5):622–630. - PubMed
    1. Ouachée-Chardin M, Elie C, de Saint Basile G, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006;117(4):e743–750. - PubMed
    1. Baker KS, Filipovich AH, Gross TG, et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2008;42(3):175–180. - PubMed
    1. Cesaro S, Locatelli F, Lanino E, et al. Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica. 2008;93(11):1694–1701. - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources